# Low-dose naltrexone (LDN)

Rating: Speculative — Little primary evidence yet: mechanism, anecdote or tradition
Type: Compound
Updated: 2026-08-06
Canonical: https://heretic.bio/articles/low-dose-naltrexone-ldn-evidence-taxonomy.html

> LDN is naltrexone at about a tenth of the addiction dose, used off-label for fibromyalgia, Crohn's, MS, ME/CFS and long COVID. The best evidence is a single small randomized trial in Crohn's disease showing symptom improvement and mucosal healing; the long COVID data is four uncontrolled studies totaling 155 patients. It is safe and cheap, but every non-addiction use is unproven, largely because no sponsor funds trials of a generic drug.

## Overview

Low-dose naltrexone (LDN) is the **off-label** use of naltrexone — a competitive opioid receptor antagonist FDA-approved at 50–100 mg/day for opioid use disorder and alcohol use disorder — administered at about a tenth of that (published studies mostly used 1–5 mg/day, most often 4.5 mg) to achieve anti-inflammatory, immunomodulatory, and analgesic effects through mechanisms distinct from its primary opioid-blocking action.

LDN is widely prescribed by integrative and functional medicine practitioners for fibromyalgia, ME/CFS, Crohn's disease, multiple sclerosis, complex regional pain syndrome (CRPS), various autoimmune conditions, and increasingly Long COVID. It is **not FDA-approved** for any of these indications. Naltrexone itself is generic and inexpensive; no commercial sponsor has funded large Phase 3 trials for LDN, which is the principal reason the evidence base remains modest.

## Mechanism of Action

LDN acts through several non-mutually-exclusive pathways, distinct from the high-dose opioid blockade used in addiction medicine:

  * **Opioid Growth Factor Receptor (OGFr) antagonism** — Transient blockade of OGFr (the receptor for opioid growth factor / met-enkephalin) appears to promote cell proliferation and tissue repair. First characterized in intestinal epithelial and cancer-cell models.
  * **Toll-Like Receptor 4 (TLR4) modulation** — LDN antagonizes TLR4 signaling on microglia and other innate immune cells, reducing production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and attenuating microglial activation in the CNS.
  * **Transient opioid receptor antagonism → rebound** — Brief nightly blockade of μ-opioid receptors is hypothesized to cause a compensatory upregulation of endogenous opioids (β-endorphin, met-enkephalin) and increased opioid receptor expression.
  * **TRPM3 ion channel restoration** — Mechanistic studies suggest LDN may restore TRPM3 channel function, with downstream effects on calcium signaling in sensory neurons. Mechanism inferred from indirect data.
  * **Hormesis-like dose response** — Beneficial effects emerge only at low doses; standard opioid-blocking doses do not produce these immunomodulatory benefits.



## Evidence Separation

### Crohn's Disease (Tier 2)

  * **Pilot open-label (2007) — PMID[17222320](https://pubmed.ncbi.nlm.nih.gov/17222320/)** — Smith JP et al. _Am J Gastroenterol_ 2007;102(4):820–828. Mean CDAI dropped significantly (p=0.01); 89% response rate, 67% remission. Most common AE: sleep disturbance (n=7). No laboratory abnormalities.
  * **Randomized placebo-controlled trial (2011) — PMID[21380937](https://pubmed.ncbi.nlm.nih.gov/21380937/)** — Smith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, Zagon IS. _Dig Dis Sci_ 2011;56(7):2088–2097. doi [10.1007/s10620-011-1653-7](https://doi.org/10.1007/s10620-011-1653-7). [NCT00663117](https://clinicaltrials.gov/study/NCT00663117). Penn State College of Medicine. Double-blind, placebo-controlled, 12-week primary endpoint with pseudo-crossover (all patients received open-label LDN for 3 additional months). Primary outcome: ≥70-point CDAI reduction at 12 weeks; secondary: endoscopic mucosal healing with biopsy. LDN-treated subjects showed significant CDAI improvement and histological reversal of inflammation; placebo-armors did not.
  * **Evidence grade** : Modest but consistent across pilot + RCT from a single investigative team. Limitations: small n, single center, unblinded follow-on phase, lack of independent replication in large RCTs.



### Multiple Sclerosis (Tier 3)

  * Small pilot trials and observational reports (e.g., Cree et al., 2010 — secondary progressive MS) suggest symptomatic benefit (fatigue, pain, quality of life), but no large confirmatory RCT.
  * Mechanism hypotheses (TLR4 microglial modulation) biologically plausible but unproven for MS disease modification.



### Fibromyalgia (Tier 3)

  * Multiple small RCTs and observational series (e.g., Younger et al., 2013) suggest reductions in pain, fatigue, and inflammatory cytokines. Sample sizes small; effect sizes moderate; independent replication limited.



### ME/CFS (Tier 3)

  * Observational cohorts (e.g., Bolton et al.) report symptom improvement in subsets of patients. No RCT-grade evidence.



### Long COVID / Post-COVID-19 Condition (Tier 3, evolving)

  * **Systematic review (May 2025) — Byambasuren et al., medRxiv 2025 (Bond University, Institute for Evidence-Based Healthcare)**. Reviewed published and registered studies up to May 2025. Findings:
  * **0 RCTs** identified.
  * 4 pre–post observational studies, n=155 total.
  * Pooled Hedges' g (negative = improvement):
  * Fatigue: g = −0.74 (moderate)
  * Brain fog: g = −0.53 (moderate)
  * Sleep: g = −0.xx (moderate, magnitude not captured in source)
  * Author conclusion: "While current research is not conclusive a therapeutic trial of LDN in Long COVID is reasonable and safe and can improve fatigue, sleep, pain, brain fog and daily function at doses of 1–6 mg/day."
  * **Evidence grade** : Preliminary. Effect sizes encouraging but biased by uncontrolled pre–post design (regression to the mean, placebo effect, natural history of Long COVID all confound).



### Other Investigated Indications (Tier 3, limited)

  * Complex regional pain syndrome (CRPS)
  * Hailey-Hailey disease, psoriasis, hidradenitis suppurativa, rheumatoid arthritis (dermatology/autoimmune small series)
  * Gulf War Illness (small trials)



## Preclinical / Mechanistic

  * **OGFr antagonism** demonstrated in intestinal epithelial cells, neuroblastoma, and animal colitis models.
  * **TLR4 modulation** on microglia reduces pro-inflammatory cytokine release in vitro and in animal models of neuroinflammation.
  * **Animal colitis models** (DSS-induced) showed that intermittent low-dose naltrexone reduced bowel inflammation and improved inflammatory index (precedent for Crohn's RCTs).
  * **Cancer biology** : OGFr pathway explored as a target in pancreatic and other cancers; high-dose naltrexone + chemotherapy combinations investigated. Distinct from LDN; do not conflate.



## Uses

Indication | Notes  
---|---  
Crohn's disease | Most studied dose; sleep disturbance common initial side effect  
Fibromyalgia | —  
ME/CFS | Patient-reported best tolerated at lower doses  
Multiple sclerosis | Small trial doses  
Long COVID (observational) | Wide range; titration common  
  
## Safety Profile

Aspect | Assessment  
---|---  
**Acute toxicity** | Very low. Naltrexone at standard doses has well-characterized safety; LDN extrapolated safety.  
**Common side effects** | Vivid dreams, sleep disturbance, transient headache, GI upset. Usually self-limited or mitigated by dose reduction.  
**Contraindications** | Concurrent opioid use (precipitates withdrawal); acute hepatitis or liver failure.  
**Drug interactions** | Opioid-containing medications (analgesics, cough suppressants, MAT such as buprenorphine/methadone — LDN blocks these).  
**Pregnancy/breastfeeding** | Insufficient data; naltrexone is category C at standard doses.  
**Long-term safety** | No long-term safety studies specifically for LDN; experience from addiction medicine suggests standard-dose naltrexone is well tolerated chronically.  
**FDA status** | Naltrexone approved (high-dose); **LDN is off-label** for all non-addiction indications.  
  
## Regulatory & Commercial Landscape

  * **Pricing** : Naltrexone generic, ~$0.30–$1/day at LDN doses; specialty compounding $30–$100/month.
  * **LDN Research Trust, LDN Science** — patient advocacy and information hubs.
  * **Claims audit** : Cannot claim "cures" or "treats" FDA-unapproved indications. Permitted language: investigational; small-trial/observational data; off-label use.



## Evidence Summary Table

Indication | Best evidence tier | PMIDs / Source | Effect size | Caveats  
---|---|---|---|---  
Crohn's disease | Tier 2 (small RCT + open-label) | 21380937, 17222320 | CDAI ↓, mucosal healing | Single center, small n, single team  
Fibromyalgia | Tier 3 (small RCTs, obs) | Younger 2013 | Pain/fatigue ↓ | Independent replication limited  
Multiple sclerosis | Tier 3 (pilot) | Cree 2010 | Symptoms ↓ | No disease-modifying evidence  
ME/CFS | Tier 3 (observational) | Bolton | Symptoms ↓ | No RCTs  
Long COVID | Tier 3 (pre–post obs) | Byambasuren 2025 medRxiv | Fatigue g −0.74; brain fog −0.53 | 0 RCTs; n=155 total  
Autoimmune derm | Tier 3 (case series) | various | Variable | Heterogeneous conditions

## Sources

1. PMID 17222320 — Smith JP et al. Am J Gastroenterol 2007;102(4):820–828 — open-label pilot in active Crohn's (n=17), 67% remission (PubMed 17222320)
2. PMID 21380937 — Smith JP et al. Dig Dis Sci 2011;56(7):2088–2097 — RCT, naltrexone 4.5 mg in active Crohn's, mucosal healing demonstrated (PubMed 21380937)
3. DOI 10.1007/s10620-011-1653-7 (DOI 10.1007/s10620-011-1653-7)
4. NCT00663117 — Penn State Crohn's RCT registry entry (NCT00663117)